OCGN Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -1816.75% compared to Ocugen's net margin of -148.33%. Ocugen's return on equity of -171.04% beat Editas Medicine's return on equity of -100%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1156.28%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 156.85%. Given that Ocugen has higher upside potential than Editas Medicine, analysts believe Ocugen is more attractive than Editas Medicine.

Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Editas Medicine has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.581%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than Editas Medicine quarterly revenues of $30.6M. Ocugen's net income of -$13.9M is higher than Editas Medicine's net income of -$45.4M. Notably, Ocugen's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 35.90x versus 3.72x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

EyePoint Pharmaceuticals has a net margin of -1816.75% compared to Ocugen's net margin of -357.26%. Ocugen's return on equity of -171.04% beat EyePoint Pharmaceuticals's return on equity of -50.34%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1156.28%. On the other hand EyePoint Pharmaceuticals has an analysts' consensus of $33.00 which suggests that it could grow by 406.14%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison EyePoint Pharmaceuticals has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.932%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. EyePoint Pharmaceuticals pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than EyePoint Pharmaceuticals quarterly revenues of $11.6M. Ocugen's net income of -$13.9M is higher than EyePoint Pharmaceuticals's net income of -$41.4M. Notably, Ocugen's price-to-earnings ratio is -- while EyePoint Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 35.90x versus 8.48x for EyePoint Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -1816.75% compared to Ocugen's net margin of -225.53%. Ocugen's return on equity of -171.04% beat Insmed's return on equity of -41989.34%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1156.28%. On the other hand Insmed has an analysts' consensus of $95.66 which suggests that it could grow by 25%. Given that Ocugen has higher upside potential than Insmed, analysts believe Ocugen is more attractive than Insmed.

Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison Insmed has a beta of 1.280, suggesting its more volatile than the S&P 500 by 27.99%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than Insmed quarterly revenues of $104.4M. Ocugen's net income of -$13.9M is higher than Insmed's net income of -$235.5M. Notably, Ocugen's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 35.90x versus 34.51x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -1816.75% compared to Ocugen's net margin of 21.57%. Ocugen's return on equity of -171.04% beat TG Therapeutics's return on equity of 12.81%.

Ocugen has a consensus price target of $6.75, signalling upside risk potential of 1156.28%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 4.88%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.

Ocugen has a beta of 3.883, which suggesting that the stock is 288.285% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.

Ocugen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocugen pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocugen quarterly revenues are $764K, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocugen's net income of -$13.9M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocugen's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 291.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocugen is 35.90x versus 19.45x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.